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Experience	  of	  using	  Bevacizumab	  in	  Epithelial	  Ovarian,	  Fallopian	  Tube	  and	  Primary	  Peritoneal	  Cancers	  in	  a	  Single	  Centre	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INTRODUCTION 
RESULTS 
Bevacizumab	  is	  a	  monoclonal	  an0body	  targe0ng	  vascular	  endothelial	  growth	  factor.	  
It	   has	   demonstrated	   improved	   progression-­‐free	   survival	   (PFS)	   and	   overall	   survival	  
(OS)	  when	  used	  with	  chemotherapy	  in	  newly	  diagnosed	  ovarian	  cancer,	  in	  par0cular	  
high-­‐risk	   pa0ents	   who	   has	   subop0mally	   debulked	   stage	   III	   or	   stage	   IV	   disease.	  
Furthermore,	  the	  addi0on	  of	  bevacizumab	  to	  chemotherapy	  has	  also	  demonstrated	  
prolonged	  PFS	  in	  pa0ents	  with	  recurrent	  disease.	  	  
With	  acceptable	  toxicity,	  combina0on	  of	  bevacizumab	  and	  chemotherapy	  may	  be	  considered	  as	  treatment	  modality	  in	  newly	  diagnosed	  subop0mally	  debulked	  stage	  III	  or	  stage	  IV	  ovarian	  cancer	  as	  well	  as	  in	  recurrent	  ovarian	  cancer.	  	  
 
The	  aim	  of	  this	  study	  is	  to	  review	  the	  use	  of	  bevacizumab	  in	  epithelial	  ovarian,	  
fallopian	  tube	  and	  primary	  peritoneal	  cancers	  in	  our	  centre.	  
•  41	  pa0ents	  received	  bevacizumab	  for	  epithelial	  ovarian,	  fallopian	  tube	  or	  primary	  peritoneal	  cancer,	  of	  which	  24	  were	  for	  primary	  treatment	  and	  17	  for	  recurrent	  disease.	  	  
•  Of	  24	  pa0ents	  who	  received	  bevacizumab	  as	  primary	  treatment,	  the	  median	  age	  was	  52	  years,	  and	  12.5%	  of	  the	  pa0ents	  had	  early-­‐stage	  high-­‐risk	  disease,	  87.5%	  had	  FIGO	  stage	  III	  or	  IV	  disease,	  45.8%	  had	  a	  serous	  adenocarcinoma,	  and	  54.2%	  had	  residual	  
disease	  aQer	  debulking	  surgery.	  	  
•  Of	  17	  pa0ents	  who	  received	  bevacizumab	  for	  recurrent	  disease,	  the	  median	  age	  was	  52	  years,	  and	  94.1%	  of	  the	  pa0ents	  were	  having	  their	  ﬁrst	  recurrence,	  64.7%	  had	  pla0num-­‐sensi0ve	  disease	  and	  41.2%	  had	  a	  serous	  adenocarcinoma.	  	  
•  Grade	  2	  or	  higher	  hypertension	  and	  proteinuria	  occured	  in	  24.4%	  and	  12.2%	  of	  pa0ents,	  respec0vely.	  
•  Bevacizumab	  was	  discon0nued	  in	  7.3%	  of	  pa0ents	  due	  to	  adverse	  events	  and	  31.7%	  due	  to	  inadequate	  therapeu0c	  response.	  
Table	  2:	  Summary	  of	  bevacizumab	  related	  adverse	  events	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CONCLUSION 
MATERIAL & METHODS 
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Pa0ents	   receiving	  bevacizumab	   for	   epithelial	   ovarian,	   fallopian	   tube	   and	  primary	  
peritoneal	   cancer	   at	   the	   Division	   of	   Gynaecological	   Oncology,	   Queen	   Mary	  
Hospital,	  The	  University	  of	  Hong	  Kong	  between	  January	  2011	  and	  December	  2015	  
were	   included.	   A	   retrospec0ve	   chart	   review	   was	   performed.	   Main	   outcome	  
measures	  were	  adverse	  events	  and	  PFS.	  
Table	  1:	  Pa0ents	  characteris0cs	  
Adverse	  events	   All	  (N=41)	  No.	  of	  paIents	  (%)	  
Primary	  (N=24)	  
No.	  of	  paIents	  (%)	  
Recurrence	  (N=17)	  
No.	  of	  paIents	  (%)	  
Hypertension	   	   	   	  
	  	  	  Grade	  2	   1	  (2.4)	   0	  (0)	   1	  (5.9)	  
	  	  	  Grade	  3	   9	  (21.9)	   7	  (29.2)	   2	  (11.8)	  
Proteinuria	   	   	   	  
	  	  	  Grade	  2	   2	  (4.9)	   2	  (8.3)	   0	  (0)	  
	  	  	  Grade	  3	   3	  (7.3)	   2	  (8.3)	   1	  (5.9)	  
Bleeding	   	   	   	  
	  	  	  Grade	  3	  haematuria	   1	  (2.4)	   0	  (0)	   1	  (5.9)	  
Infusion	  related	  reac0on	   	   	   	  
	  	  	  Grade	  2	   1	  (2.4)	   1	  (4.2)	   0	  (0)	  





PRIMARY	  TREATMENT	  	  
•  Median	  PFS	  was	  18.0	  months	  (95%	  CI	  13.6	  to	  22.4)	  
•  Es0mated	  mean	  OS	  was	  42.7	  months	  (95%	  CI	  35.2	  to	  50.3)	  
RECURRENT	  DISEASE	  
•  Median	  PFS	  was	  11.0	  months	  (95%	  CI	  8.4	  to	  13.6)	  
•  Es0mated	  mean	  OS	  was	  18.8	  months	  (95%	  CI	  13.7	  to	  23.9)	  
PFS	  and	  OS	  in	  pa0ents	  on	  bevacizumab	  for	  recurrence	  PFS	  and	  OS	  in	  pa0ents	  on	  bevacizumab	  as	  ﬁrst-­‐line	  treatment	  
	  	   	  	  
CharacterisIcs	   Recurrence	  (N=17)	  No.	  of	  paIents	  (%)	  
Median	  age	  (range)	  (years)	   52	  (36-­‐66)	  	  
Histology	  at	  diagnosis	   	  
	  	  	  Serous	  adenocarcinoma	   7	  (41.2)	  
	  	  	  Clear	  cell	  adenocarcinoma	   3	  (17.6)	  
	  	  	  Endometriod	  adenocarcinoma	   2	  (11.8)	  
	  	  	  Mixed	  adenocarcinoma	   5	  (29.4)	  
Dura0on	  from	  previous	  pla0num-­‐
based	  treatment	  to	  recurrence	   	  
	  	  	  <	  6	  months	  (Pla0num-­‐resistant)	   5	  (29.4)	  
	  	  	  ≥	  6	  months	  (Pla0num-­‐sensi0ve)	   11	  (64.7)	  
	  	  	  No	  previous	  chemotherapy	   1	  (5.9)	  
Debulking	  surgery	  for	  recurrence	   	  
	  	  	  Yes	   2	  (11.8)	  
	  	  	  No	   15	  (88.2)	  
Chemotherapy	  agents	  used	   	  
	  	  	  Carbopla0n	  and	  gemcitabine	   10	  (58.8)	  
	  	  	  Carbopla0n	  and	  paclitaxel	   4	  (23.5)	  
	  	  	  Liposomal	  doxorubicin	   2	  (11.8)	  
	  	  	  Weekly	  paclitaxel	   1	  (5.9)	  
CharacterisIcs	   Primary	  (N=24)	  No.	  of	  paIents	  (%)	  
Median	  age	  (range)	  (years)	   52	  (38-­‐78)	  
Histology	   	  
	  	  	  Serous	  adenocarcinoma	   11	  (45.8)	  
	  	  	  Clear	  cell	  adenocarcinoma	   6	  	  (25.0)	  
	  	  	  Endometriod	  adenocarcinoma	   1	  (4.2)	  
	  	  	  Mucinous	  adenocarcinoma	   1	  (4.2)	  
	  	  	  Mixed	  adenocarcinoma	   5	  (20.8)	  
FIGO	  Stage	   	  
	  	  	  I	   2	  (8.3)	  
	  	  	  II	   1	  (4.2)	  
	  	  	  III	   18	  (75.0)	  
	  	  	  IV	   3	  (12.5)	  
Neoadjuvant	  chemotherapy	   	  
	  	  	  Yes	   2	  (8.3)	  
	  	  	  No	   22	  (91.7)	  
Op0mal	  debulking	   	  
	  	  	  No	  residual	  disease	   11	  (45.8)	  
	  	  	  Residual	  desease	  ≤1cm	   2	  (8.3)	  
	  	  	  Subop0mal	  debulking	   11	  (45.8)	  
